title: Epstein-Barr virus infections after allogeneic stem cell transplantation: a comparison between non-malignant and malignant hematological disorders.
abstract: Hematological cancers and non-malignant hematological disorders are biologically diverse conditions and are treated differently. We compared the pattern of EBV infections following allogeneic stem cell transplantation between the above two groups of hematological disorders. Eighty-three transplants were evaluated over a consecutive 7-year period at a single center. No difference was found in the incidence of post-transplant EBV infections between the two groups, though a higher median peak viral load was noted in the non-malignant group (P=0·04). Pre-transplant immunosuppressive therapy with antithymocyte globulin (ATG) significantly increased the risk of post-transplant EBV infections (P=0·04) in the non-malignant group patients. No significance was found for prior cytotoxic chemotherapy among the malignant group of patients. Alemtuzumab based conditioning was not associated with an increased risk for EBV infections in either of the groups. Treatment with two or more courses of ATG was found to be significantly associated with post-transplant EBV-related PTLD (P=0·01). Post-transplant EBV infections did not influence overall survival (non-malignant, P=0·66; malignant, P=0·41) in either of the subgroups. There were no deaths directly attributable to EBV infections.
authors.affiliation: Department of Hematology, St George's Hospital, London, UK. serajul@doctors.org.uk
authors.forename: Md Serajul
authors.initials: MS
authors.lastname: Islam
authors.forename: Parameswaran
authors.initials: P
authors.lastname: Anoop
authors.forename: Edward C
authors.initials: EC
authors.lastname: Gordon-Smith
authors.forename: Phil
authors.initials: P
authors.lastname: Rice
authors.forename: Preeti
authors.initials: P
authors.lastname: Datta-Nemdharry
authors.forename: Judith C W
authors.initials: JC
authors.lastname: Marsh
mesh_terms: D000293:Adolescent; D000328:Adult; D000914:Antibodies, Viral / Q000097:blood / Q000276:immunology; D000961:Antilymphocyte Serum / Q000009:adverse effects / Q000627:therapeutic use; D004279:DNA, Viral / Q000235:genetics; D004797:Enzyme-Linked Immunosorbent Assay; D020031:Epstein-Barr Virus Infections / Q000175:diagnosis / Q000209:etiology* / Q000821:virology; D005260:Female; D006402:Hematologic Diseases / Q000601:surgery*; D019337:Hematologic Neoplasms / Q000601:surgery*; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects* / Q000379:methods; D004854:Herpesvirus 4, Human / Q000235:genetics / Q000276:immunology; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D016133:Polymerase Chain Reaction; D016019:Survival Analysis; D014184:Transplantation, Homologous; D055815:Young Adult
chemical_list: D000914:Antibodies, Viral; D000961:Antilymphocyte Serum; D004279:DNA, Viral; D007166:Immunosuppressive Agents